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Summary 
Shiga toxin–producing Escherichia coli (STEC) are a leading cause of bacterial enteric infections in the United States. Prompt, 
accurate diagnosis of STEC infection is important because appropriate treatment early in the course of infection might decrease 
the risk for serious complications such as renal damage and improve overall patient outcome. In addition, prompt laboratory 
identification of STEC strains is essential for detecting new and emerging serotypes, for effective and timely outbreak responses 
and control measures, and for monitoring trends in disease epidemiology. Guidelines for laboratory identification of STEC infec-
tions by clinical laboratories were published in 2006 (1). This report provides comprehensive and detailed recommendations for 
STEC testing by clinical laboratories, including the recommendation that all stools submitted for routine testing from patients 
with acute community-acquired diarrhea (regardless of patient age, season of the year, or presence or absence of blood in the stool) 
be simultaneously cultured for E. coli O157:H7 (O157 STEC) and tested with an assay that detects Shiga toxins to detect non-
O157 STEC. The report also includes detailed procedures for specimen selection, handling, and transport; a review of culture and 
nonculture tests for STEC detection; and clinical considerations and recommendations for management of patients with STEC 
infection. Improving the diagnostic accuracy of STEC infection by clinical laboratories should ensure prompt diagnosis and treat-
ment of these infections in patients and increase detection of STEC outbreaks in the community.
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Introduction
Shiga toxin–producing E. coli (STEC) cause approximately 
100,000 illnesses, 3,000 hospitalizations, and 90 deaths annu-
ally in the United States, according to the last estimate in 1999 
(2). Most reported STEC infections in the United States are 
caused by E. coli O157:H7, with an estimated 73,000 cases 
occurring each year (2). Non-O157 STEC bacteria also are 
important causes of diarrheal illness in the United States; at 
least 150 STEC serotypes have been associated with outbreaks 
and sporadic illness (2–4). In the United States, six non-O157 
serogroups (O26, O45, O103, O111, O121, and O145) 
account for the majority of reported non-O157 STEC infec-
tions (5). 
The toxins produced by STEC were named based on their 
similarity in structure and function to Shiga toxins produced 
by Shigella dystenteriae type 1 (6). Shiga toxin 1 (Stx1) is 
neutralized by antibodies against Shiga toxin, whereas Shiga 
toxin 2 (Stx2) is not neutralized by antibodies against Shiga 
toxin but is neutralized by homologous antibodies. STEC are 
also referred to as verocytotoxigenic E. coli; STEC that cause 
human illness are also referred to as enterohemorrhagic E. 
coli. In this report, all E. coli that produce a Shiga toxin are 
referred to as STEC. STEC serotypes are named according to 
their somatic (O) and flagellar (H) antigens. In this report, all 
STEC with the O antigen 157 are referred to as O157 STEC, 
regardless of whether the H7 antigen has been identified or 
Shiga toxin production has been confirmed. STEC with other 
O antigens are referred to as non-O157 STEC or by their 
specific O antigen. 
STEC infection causes acute, often bloody, diarrhea. 
Approximately 8% of persons who receive a diagnosis of O157 
STEC infection develop hemolytic uremic syndrome (HUS), 
a life-threatening condition characterized by thrombocytope-
nia, hemolytic anemia, and renal failure (7–9). Thrombotic 
thrombocytopenic purpura (TTP), a syndrome with signs 
and symptoms that are similar to those of HUS, is typically 
diagnosed in adults. When TTP is diagnosed after a diarrheal 
illness, the condition is usually caused by infection with O157 
STEC or another STEC. In this report, regardless of the age of 
the patient, TTP diagnosed after a diarrheal illness is referred 
to as HUS (10). 
Whether an illness progresses to HUS depends on strain 
virulence and host factors (11). Although most persons with 
diarrhea-associated HUS have an O157 STEC infection, 
certain non-O157 STEC strains also can lead to HUS (3). 
The virulence of non-O157 STEC is partly determined by the 
toxins they produce; non-O157 STEC strains that produce 
only Stx2 are more often associated with HUS than strains that 
produce only Stx1 or that produce both Stx1 and Stx2 (12). 
STEC infections and HUS occur in persons of all ages, but 
the incidence of STEC infection is highest in children aged <5 
years, as is the risk for HUS (9). Although STEC infections 
are more common during summer months, they can occur 
throughout the year. 
STEC transmission occurs through consumption of a wide 
variety of contaminated foods, including undercooked ground 
beef, unpasteurized juice, raw milk, and raw produce (e.g., 
lettuce, spinach, and alfalfa sprouts); through ingestion of 
contaminated water; through contact with animals or their 
environment; and directly from person to person (e.g., in child-
care settings). Both O157 STEC and O111 STEC have a low 
infectious dose (<100 organisms) (13); the infectious dose of 
other serogroups is not known.
Prompt and accurate diagnosis of STEC infection is impor-
tant because appropriate treatment with parenteral volume 
expansion early in the course of infection might decrease 
renal damage and improve patient outcome (14). In addition, 
because antibiotic therapy in patients with STEC infections 
might be associated with more severe disease, prompt diagnosis 
is needed to ensure proper treatment. Furthermore, prompt 
laboratory identification of STEC strains is essential for 
implementation of control measures, for effective and timely 
outbreak responses, to detect new and emerging serotypes, and 
to monitor trends in disease epidemiology (1,15,16).
Most O157 STEC isolates can be readily identified in the 
laboratory when grown on sorbitol-containing selective media 
because O157 STEC cannot ferment sorbitol within 24 hours. 
However, many clinical laboratories do not routinely culture 
stool specimens for O157 STEC. In addition, selective and 
differential media are not available for the culture of non-O157 
STEC, and even fewer laboratories culture stool specimens for 
these bacteria than for O157 STEC.
Recently, the increased use of enzyme immunoassay (EIA) 
or polymerase chain reaction (PCR) to detect Shiga toxin or 
the genes that encode the toxins (stx1 and stx2) has facilitated 
the diagnosis of both O157 and non-O157 STEC infections. 
Although EIA and other nonculture tests are useful tools for 
diagnosing STEC infection, they should not replace culture; 
a pure culture of the pathogen obtained by the clinical labora-
tory (O157 STEC) or the public health laboratory (non-O157 
STEC) is needed for serotyping and molecular characteriza-
tion (e.g., pulsed-field gel electrophoresis [PFGE] patterns), 
which are essential for detecting, investigating, and controlling 
STEC outbreaks. 
Simultaneous culture of stool for O157 STEC and EIA 
testing for Shiga toxin is more effective for identifying STEC 
infections than the use of either technique alone (17,18). 
Because virtually all O157 STEC have the genes for Stx2 (stx2) 
and intimin (eae), which are found in strains that are associated 
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with severe disease (5,12,19–22), detection of O157 STEC 
should prompt immediate initiation of steps such as parenteral 
volume expansion to reduce the risk for renal damage in the 
patient and the spread of infection to others. 
Guidelines for clinical and laboratory identification of STEC 
infections have been previously published (1); this report pro-
vides the first comprehensive and detailed recommendations 
for isolation and identification of STEC by clinical laborato-
ries. The recommendations are intended primarily for clinical 
laboratories but also are an important reference for health-care 
providers, public health laboratories, public health authorities, 
and patients and their advocates.
Recommendation for Identification 
of STEC by Clinical Laboratories
All stools submitted for testing from patients with acute 
community-acquired diarrhea (i.e., for detection of the enteric 
pathogens Salmonella, Shigella, and Campylobacter) should be 
cultured for O157 STEC on selective and differential agar. 
These stools should be simultaneously assayed for non-O157 
STEC with a test that detects the Shiga toxins or the genes 
encoding these toxins. All O157 STEC isolates should be 
forwarded as soon as possible to a state or local public health 
laboratory for confirmation and additional molecular charac-
terization (i.e., PFGE analysis and virulence gene characteriza-
tion). Detection of STEC or Shiga toxin should be reported 
promptly to the treating physician, to the public health labora-
tory for confirmation, isolation, and subsequent testing of the 
organism, and to the appropriate public health authorities for 
case investigation. Specimens or enrichment broths in which 
Shiga toxin or STEC are detected but from which O157 STEC 
are not recovered should be forwarded as soon as possible to 
a state or local public health laboratory.
Benefits of Recommended Testing 
Strategy
Identification of Additional STEC 
Infections and Detection of All STEC 
Serotypes
Evidence indicates that STEC might be detected as fre-
quently as other bacterial pathogens. In U.S. studies, STEC 
were detected in 0%–4.1% of stools submitted for testing 
at clinical laboratories, rates similar to those of Salmonella 
species (1.9%–4.8%), Shigella species (0.2%–3.1%), and 
Campylobacter species (0.9%–9.3%) (9,17,23–31). In one 
study, the proportion of stools with STEC detected varied 
by study site (9); O157 STEC were more commonly isolated 
than some other enteric pathogens in northern states. The 
laboratory strategy of culturing stool while simultaneously 
testing for Shiga toxin is more sensitive than other strategies for 
STEC identification and ensures that all STEC serotypes will 
be detected (17,18,30,31) (Table 1). In addition, immediate 
culture ensures that O157 STEC bacteria are detected within 
24 hours of the initiation of testing. 
Early Diagnosis and Improved Patient 
outcome 
Early diagnosis of STEC infection is important for deter-
mining the proper treatment promptly. Initiation of parenteral 
volume expansion early in the course of O157 STEC infection 
might decrease renal damage and improve patient outcome 
(14). Conversely, certain treatments can worsen patient out-
comes; for example, antibiotics might increase the risk for 
HUS in patients infected with O157 STEC, and antidiarrheal 
medications might worsen the illness (32). Early diagnosis of 
STEC infection also might prevent unnecessary procedures or 
treatments (e.g., surgery or corticosteroids for patients with 
severe abdominal pain or bloody diarrhea) (33–35). 
Prompt Detection of outbreaks
Prompt laboratory diagnosis of STEC infection facilitates 
rapid subtyping of STEC isolates by public health labora-
tories and submission of PFGE patterns to PulseNet, the 
national molecular subtyping network for foodborne disease 
surveillance (36). Rapid laboratory diagnosis and subtyping 
of STEC isolates leads to prompt detection of outbreaks, 
timely public health actions, and detection of emerging STEC 
strains (37,38). Delayed diagnosis of STEC infections might 
lead to secondary transmission in homes, child-care settings, 
nursing homes, and food service establishments (39,40–44) 
and might delay detection of multistate outbreaks related to 
widely distributed foods (39,45). Outbreaks caused by STEC 
with multiple serogroups (46) or PFGE patterns (47) have 
been documented. 
Criteria for STEC Testing and 
Specimen Selection 
All stool specimens from patients with acute onset of 
community-acquired diarrhea and from patients with possible 
HUS should be tested for STEC. Many infections are missed 
with selective STEC testing strategies (e.g., testing only 
specimens from children, testing only during summer months, 
or testing only stools with white blood cells or blood). Some 
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patients with STEC infection do not have visibly bloody stools, 
whereas some persons infected with other pathogens do have 
bloody stools (3,9,48,49). Therefore, the absence of blood in 
the stool does not rule out the possibility of a STEC-associated 
diarrheal illness; both O157 and non-O157 strains have been 
isolated from patients with nonbloody diarrhea (30–32,49–51). 
Similarly, white blood cells are often but not always detected in 
the stools of patients with STEC infection and should not be 
used as a criterion for STEC testing (9,39). Selective testing on 
the basis of patient age or season of the year also might result 
in undetected infections. Although STEC bacteria are isolated 
more frequently from children, almost half of all STEC isolates 
are from persons aged >12 years (5,9,49,52); testing for STEC 
only in specimens from children would result in many missed 
infections. In addition, although STEC infections are more 
common in summer months, infections and outbreaks occur 
throughout the year (5,9,32). 
Stools should be tested as early as possible in the course of 
illness; bacteria might be difficult or impossible to detect in 
the stool after 1 week of illness (53,54), and the Shiga toxin 
genes might be lost by the bacteria (55). In certain instances, 
retrieval of plates from cultures obtained earlier in the illness 
that were not initially evaluated for STEC might be necessary. 
Early detection of STEC and proper patient management 
are especially important among children because they are the 
age group most likely to have an infection that develops into 
HUS (32).
STEC testing might not be warranted, or selective STEC 
testing might be appropriate, for patients who have been hos-
pitalized for ≥3 days; infection in this setting is more likely to 
be caused by Clostridium difficile toxin than another enteric 
pathogen (39). However, when a patient is admitted to the 
hospital with symptoms of a diarrheal illness, a stool culture 
with STEC testing might be appropriate, regardless of the 
number of days of hospitalization. In addition, although few 
hospital-associated outbreaks of STEC have been reported, if 
a hospitalized patient is involved in a hospital-associated out-
break of diarrhea, STEC testing should be performed if tests 
are also being conducted for other bacterial enteric pathogens 
(e.g., Salmonella). Although chronic diarrhea is uncommon in 
patients with STEC infection, certain STEC strains have been 
associated with prolonged or intermittent diarrhea; therefore, 
























positive sample  
available for  
isolation of STEC 
within 24 hrs Comments
Simultaneous 
culture for O157 
STEC and non-
culture assay for 
Shiga toxin
Yes Yes Yes Yes Yes Yes Recommended practice•	
Nonculture as-
say for Shiga 
toxin followed by 
culture for O157 
STEC if Shiga 
toxin assay is 
positive
No No No Yes Yes Yes Delays detection and isola-•	
tion of O157 STEC
Delays forwarding of Shiga •	
toxin–positive broths for 
isolation of non-O157 
STEC
Misses O157 STEC that •	
are not actively expressing 
toxin or have lost Shiga 
toxin genes
Nonculture assay 
for Shiga toxin 
with rapid sub-
mission to public 
health laboratory
No No No Yes Yes Yes Delays detection and isola-•	
tion of O157 STEC
Misses O157 STEC that •	
are not expressing toxin or 
have lost Shiga toxin genes
Culture for O157 
STEC
Yes Yes Yes No No No Misses sorbitol-fermenting •	
variants of O157 STEC
Misses non-O157 STEC•	
* Performance characteristics reflect use of nonculture assays for Shiga toxin with overnight enrichment broths or growth from the primary isolation plate. 
Enrichment broths are strongly recommended for the routine diagnostic testing of fecal specimens with nonculture Shiga toxin tests. Because stool 
specimens can contain inhibitors and might have few target organisms, the sensitivity of nonculture Shiga toxin tests when performed directly on stool 
specimens is generally insufficient to reliably exclude infection with the target organism (Source: Cornick NA, Jelacic S, Ciol MA, Tarr PI. Escherichia coli 
O157:H7 infections: discordance between filterable fecal Shiga toxin and disease outcome. J Infect Dis 2002;186:57–63.)
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testing for Shiga toxin should be considered if an alternative 
diagnosis (e.g., ulcerative colitis) has not been identified (56). 
Testing multiple specimens is likely unnecessary unless the 
original specimen was not transported or tested appropriately 
or the test results are not consistent with the patient’s signs and 
symptoms. After STEC bacteria are detected in a specimen, 
additional specimens from the same patient do not need to be 
tested for diagnostic purposes.
To prevent additional transmission of infection, certain 
persons (e.g., food-service workers and children who attend 
child-care facilities or adults who work in these facilities) who 
receive a diagnosis of STEC infection might be required by 
state law or a specific facility to prove that they are no longer 
shedding the bacteria after treatment and before returning to 
the particular setting. Follow-up specimens are usually tested 
by state public health laboratories. No data exist regarding the 
effectiveness of excluding postsymptomatic carriers of non-
O157 STEC (i.e., persons who test positive for non-O157 
STEC but no longer have symptoms) from work or school 
settings in preventing secondary spread. 
Procedures for Collecting and 
Handling Specimens for STEC 
Diagnostic Testing 
Acceptable Specimens for Testing
Laboratories should always consult the manufacturer instruc-
tions for the assay being performed to determine procedures for 
specimen collection and handling, including specimen types 
that may be used with a particular assay or test system. The 
ideal specimen for testing is diarrheal stool; stool specimens 
should be collected as soon as possible after diarrhea begins, 
while the patient is acutely ill, and before any antibiotic treat-
ment is administered. The same specimen that is collected for 
Salmonella, Shigella, and Campylobacter testing is acceptable 
for STEC culture and Shiga toxin detection. Collecting and 
testing specimens as soon as possible after symptom onset is 
important to ensure maximal sensitivity and specificity for 
STEC detection with available commercial diagnostic assays. 
Diagnostic methods such as the Shiga toxin immunoassay that 
target traits encoded on mobile genetic elements (e.g., phages) 
are less sensitive if the elements have been lost (53,57). 
Shiga toxin testing should be performed on growth from 
broth culture or primary isolation media because this method 
is more sensitive and specific than direct testing of stool. In 
addition, because the amount of free fecal Shiga toxin in stools 
is often low, EIA testing of broth enrichments from stools or 
of growth from the primary isolation plate is recommended 
rather than direct testing of stools (58).
Although rectal swabs are often used to collect stool from 
children, swabs might not contain enough stool to culture for 
multiple enteric pathogens and to perform STEC testing. If 
rectal swabs must be used to collect specimens for STEC test-
ing, broth enrichment is recommended. Laboratories should 
consult the manufacturer instructions for information on the 
suitability of toxin testing using stool from rectal swabs. 
Commercially available assays have not been validated for 
specimens collected by endoscopy or colonoscopy. If a labora-
tory chooses to use an assay for patient testing with a specimen 
other than that included in the manufacturer’s FDA-cleared 
package insert, under the Clinical Laboratory Improvement 
Amendments (CLIA) of 1988, that laboratory must first 
establish the performance specifications for the alternative 
specimen type (59). Unless STEC are isolated, results from 
tests on alternative specimen types should be interpreted with 
caution. 
Specimen Handling
Specimens should be sent to the laboratory as soon as pos-
sible for O157 STEC culture and Shiga toxin testing. Ideally, 
specimens should be processed as soon as they are received by 
the laboratory. Specimens that are not processed immediately 
should be refrigerated until tested; if possible, they should not 
be held for >24 hours unpreserved or for >48 hours in transport 
medium. All O157 STEC isolates and all specimens or enrich-
ment broths in which Shiga toxin is detected but from which 
O157 STEC bacteria are not recovered should be forwarded to 
the public health laboratory as soon as possible in compliance 
with the receiving laboratory’s guidelines. 
Transport Media
Specimens should be transported under conditions appropri-
ate for the transport medium used and tests to be performed; 
appropriate transport conditions can be determined by review-
ing the manufacturer instructions. Stool specimens that can-
not be immediately transported to the laboratory for testing 
should be put into a transport medium (e.g., Cary-Blair) that 
is optimal for the recovery of all bacterial enteric pathogens. 
Laboratories should consult the manufacturer instructions for 
the suitability of toxin testing for stool in transport medium. If 
a laboratory must perform direct Shiga toxin testing of stool, 
the stool specimen should be refrigerated but should not be 
placed in transport medium. Direct toxin testing of stool 
should follow the manufacturer instructions. 
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Culture for STEC 
o157 STEC
O157 STEC can usually be easily distinguished from most 
E. coli that are members of the normal intestinal flora by their 
inability to ferment sorbitol within 24 hours on sorbitol-
containing agar isolation media. To isolate O157 STEC, a 
stool specimen should be plated onto a selective and differen-
tial medium such as sorbitol-MacConkey agar (SMAC) (60), 
cefixime tellurite-sorbitol MacConkey agar (CT-SMAC), or 
CHROMagar O157. After incubation for 16–24 hours at 
37°C (99°F), the plate should be examined for possible O157 
colonies, which are colorless on SMAC or CT-SMAC and are 
mauve or pink on CHROMagar O157. Both CT-SMAC and 
CHROMagar O157 are more selective than SMAC, which 
increases the sensitivity of culture for detection of O157 
STEC (61,62). Sorbitol-fermenting STEC O157:H- (i.e., 
nonmotile [NM]), a pathogen that is uncommon in the United 
States and primarily reported from Germany, might not grow 
on CT-SMAC agar because the bacteria are susceptible to 
tellurite.
To identify O157 STEC, a portion of a well-isolated colony 
(i.e., a distinct, single colony) should be selected from the cul-
ture plate and tested in O157-specific antiserum or O157 latex 
reagent as recommended by the manufacturer (63). Colonies 
that agglutinate with one of the O157-specific reagents and 
do not agglutinate with normal serum or control latex reagent 
are presumed to be O157 STEC. At least three colonies should 
be screened (CDC, unpublished data, 2009). If O157 STEC 
bacteria are identified in any one of the three colonies, no 
additional colonies need to be tested. 
The colony in which O157 STEC are detected should be 
streaked onto SMAC or a nonselective agar medium such as 
tryptic soy agar (TSA), heart infusion agar (HIA), or blood agar 
and biochemically confirmed to be E. coli (e.g., using standard 
biochemical tests or commercial automated systems) because 
other bacterial species can cross-react in O157 antiserum 
(64–66). Before confirmation is complete at the laboratory 
(which might take >24 hours), the preliminary finding of O157 
STEC should be reported to the treating clinician and should 
be documented according to laboratory policies for other 
time-sensitive, clinically important laboratory findings. The 
preliminary nature of these presumptive results and the need for 
test confirmation should be indicated in the report. After O157 
STEC colonies have been isolated, been found to agglutinate 
with O157 latex reagent, and been biochemically confirmed 
as E. coli, a written or electronic report should be provided to 
the clinician and public health authorities (Table 2). 
All O157 STEC isolates should be forwarded to the public 
health laboratory as soon as possible, regardless of whether H7 
testing has been attempted or completed. At the public health 
laboratory, O157 STEC isolates should be tested by EIA for 
Shiga toxin production or by PCR for the stx1 and stx2 genes. 
Actively motile O157 STEC strains should be tested for the 
H7 antigen. All O157 STEC strains should be subtyped by 
PFGE as soon as possible.
non-o157 STEC 
Identification of non-O157 STEC typically occurs at 
the public health laboratory and not at clinical laboratories 
(Table 3). However, this section includes the basic techniques 
for reference.
To isolate non-O157 STEC, the Shiga toxin–positive 
broth should be streaked to a relatively less selective agar 
(e.g., MacConkey agar, SMAC, Statens Serum Institut [SSI] 
enteric medium, or blood agar). Traditional enteric media 
such as Hektoen agar, xylose-lysine-desoxycholate agar, and 
Salmonella-Shigella agar inhibit many E. coli and are not rec-
ommended (67). All possible O157 STEC colonies should 
be tested in O157 latex reagent before isolation of non-O157 
STEC is attempted. Well-isolated colonies with E. coli-like 
morphology should be selected on the basis of sorbitol or 
lactose fermentation characteristics (or other characteristics 
specific to the medium used); most non-O157 STEC fer-
ment both sorbitol and lactose, although exceptions have been 
reported (CDC, unpublished data, 2009). Colonies may be 
tested for Shiga toxin production by EIA or for stx1 and stx2 
genes by PCR. Non-O157 STEC may be tested using commer-
cial O-specific antisera for the most common STEC-associated 
O antigens (i.e., O26, O45, O103, O111, O121, and O145) 
(5). Non-O157 STEC isolates should be forwarded to a public 
health laboratory for confirmation of Shiga toxin production, 
serogroup determination, and PFGE subtyping. 
nonculture Assays for Detection of 
Shiga Toxins and STEC
Nonculture assays that detect the Shiga toxins produced by 
STEC (e.g., the Shiga toxin EIA) were first introduced in the 
United States in 1995. The primary advantage of nonculture 
assays for Shiga toxin is that they can be used to detect all sero-
types of STEC. In addition, nonculture assays might provide 
results more quickly than culture. The primary disadvantage 
of nonculture based assays is that the infecting organism is not 
isolated for subsequent serotyping and a specific diagnosis of 
O157 STEC. Lack of an isolated organism limits the ability 
of physicians to predict the potential severity of the infection 
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in the patient (e.g., risk for HUS), the risk for severe illness 
in patient contacts, and the ability of public health officials 
to detect and control STEC outbreaks and monitor trends in 
STEC epidemiology. In addition, although the nonculture 
assays for Shiga toxin also detect Stx1 produced by Shigella 
dysenteriae type 1, infection with this organism is rare in the 
United States, with fewer than five cases reported each year 
(68).
Shiga Toxin Immunoassays
The Center for Devices and Radiological Health of the Food 
and Drug Administration (FDA) has approved several immu-
noassays for the detection of Shiga toxin in human specimens 
(Table 4). Because the amount of free fecal Shiga toxin in stools 
is often low (58), EIA testing of enrichment broth cultures 
incubated overnight (16–24 hours at 37°C [99°F]), rather than 
direct testing of stool specimens, is recommended. In addition, 
the manufacturer information indicates that tests performed on 
broth cultures have higher sensitivity and specificity than those 
performed on stool. No studies have determined whether one 
type of broth is most effective; MacConkey and gram-negative 
broths are both suitable.
Four FDA-approved immunoassays are available in the 
United States (Table 4). The Premier EHEC (Meridian 
Diagnostics, Cincinnati, Ohio) and the ProSpecT Shiga 
Toxin E. coli Microplate Assay (Remel, Lenexa, Kansas) 
are in a microplate EIA format; the Immunocard STAT! 
EHEC (Meridian Diagnostics, Cincinnati, Ohio) and the 
Duopath Verotoxins Gold Labeled Immunosorbent Assay 
(Merck, Germany) are lateral flow immunoassays. Both the 
Immunocard STAT! EHEC and the Duopath Verotoxins assays 
differentiate between Stx1 and Stx2; the Premier EHEC and 
the ProSpecT assays do not differentiate between Stx1 and 
Stx2. The time required for these assays, not including the 
time for overnight enrichment, ranges from 20 minutes to 4 
hours, depending on the test format used. Specific instructions 
and actual requirements for each test can be determined by 
consulting the manufacturer instructions.
Reported sensitivities and specificities of Shiga toxin immu-
noassays vary by test format and manufacturer. The standard by 
which each manufacturer evaluates its tests varies; a direct com-
parison of performance characteristics of various immunoassays 
has not been made. The clinical performance characteristics of 
each test are available in the package insert. Clinical laboratories 
should evaluate these performance characteristics and verify 
that they can obtain performance specifications comparable 
to those of the manufacturer before implementing a particular 
test system. The College of American Pathologists (69) and the 
American Proficiency Institute (70) offer proficiency testing 
for STEC immunoassays. 
Laboratories should immediately report Shiga toxin–positive 
specimens to the treating clinician and appropriate public 
health and infection control officials. Clinical laboratories 
should forward Shiga toxin–positive specimens or enrichment 
broths to a public health laboratory as soon as possible for 
isolation and additional characterization. 
In multiple studies, for reasons that are unknown, EIAs failed 
to detect a subset of O157 STEC that were readily identi-
fied on simultaneously plated SMAC agar, underscoring the 
importance of primary isolation (17,50,71–73). EIA tests also 
might have false-positive STEC results when other pathogens 
are present (1,74,75).
PCR 
PCR assays to detect the stx1 and stx2 genes are used by 
many public health laboratories for diagnosis and confirma-
TABLE 2. Documentation of Shiga toxin–producing Escherichia coli (STEC) test results in final laboratory reports
Test Result Examples of documentation in final report
Culture for 
O157 STEC
Positive Escherichia coli O157:H7 or Shiga toxin–producing E. coli O157 isolated
Negative Escherichia coli O157:H7 or Shiga toxin–producing E. coli O157 not isolated 
Culture for STEC Positive Shiga toxin–producing Escherichia coli O___:H_ isolated*
Negative Shiga toxin–producing Escherichia coli not isolated, suggesting that Shiga toxin–producing 
E. coli is not present 
Immunoassay 
detection of Shiga 
toxin antigen
Positive Shiga toxin detected by immunoassay, indicating the likely presence of a Shiga toxin–producing 
Escherichia coli such as E. coli O157:H7
Negative Shiga toxin not detected by immunoassay, suggesting that a Shiga toxin–producing Escherichia 
coli, such as E. coli O157, is not present 
Detection of Shiga 
toxin DNA (i.e., 
Shiga toxin genes)
Positive for Shiga toxin 1 
gene (stx1), Shiga toxin 2 
gene (stx2), or both
Genes for Shiga toxin 1, Shiga toxin 2, or both were detected by polymerase chain reaction, 
indicating the likely presence of a Shiga toxin–producing Escherichia coli such as O157:H7
Negative for Shiga toxin 
genes
Shiga toxin genes not detected by polymerase chain reaction, suggesting that a Shiga toxin–
producing Escherichia coli, such as O157, is not present
* Public health laboratories may determine the O antigen or send the specimen to CDC for O antigen and H antigen determination.
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tion of STEC infection. Depending on the primers used, these 
assays can distinguish between stx1 and stx2 (76–78). Assays 
also have been developed that determine the specific O group 
of an organism, detect virulence factors such as intimin and 
enterohemolysin, and can differentiate among the subtypes of 
Shiga toxins (79–81). Because these tests are not commercially 
available, they are rarely used for human disease diagnosis in 
the United States. 
Most PCR assays are designed and validated for testing 
isolated colonies taken from plated media; some assays have 
been validated for testing on stool specimens subcultured to an 
enrichment broth and incubated for 18–24 hours. Shiga toxin 
PCR assays on DNA extracted from whole stool specimens 
are not recommended because the sensitivity is low (82). The 
time required to obtain PCR assay results ranges from 3 hours 
(if an isolate is tested) to 24–36 hours (if the specimen is first 
subcultured to an enrichment broth or plate). 
DNA-based Shiga toxin gene detection is not approved 
by FDA for diagnosis of human STEC infections by clinical 
laboratories; however, public health laboratories might use this 
technique for confirmatory testing after internal validation. 
One commercial PCR kit is available to test for STEC virulence 
genes (DEC Primer Mix, Mira Vista Diagnostics, Indianapolis, 
Indiana); however, this test is labeled for research use only, 
can only be used on isolates, and is not approved by FDA for 
diagnosis of human STEC infections. Clinical laboratories 
that are considering adding a DNA-based assay to their testing 
options need to establish performance specifications for the 
assay as required by CLIA (59), and reports from such testing 
should include a disclaimer to inform clinicians that the test 
is not approved by FDA (83). No commercially available pro-
ficiency testing programs are available in the United States for 
PCR assays that target the Shiga toxin genes; however, internal 
proficiency testing events and exchanges with other laboratories 
may be used to fulfill CLIA requirements (84). 
TABLE 3. Shiga toxin–producing Escherichia coli (STEC) testing procedures typically performed by clinical and public health 
laboratories, by type of laboratory
Testing procedures typically performed*
Test performed Clinical laboratory† Public health laboratory
Culture for O157 STEC Specimens plated to selective and differential media•	
Possible STEC colonies tested for O157 antigen •	
Biochemical testing performed on O157-positive •	
colonies to identify E. coli
O157 isolates forwarded to public health laboratory•	
O157 antigen confirmed•	
H7 serology or Shiga toxin antigen or Shiga toxin •	
gene testing performed§
Culture for non-O157 STEC Not typically performed•	 Specimens plated to selective and differential media•	
Possible STEC colonies tested for Shiga toxin or •	
Shiga toxin genes
Biochemical testing performed of STEC colony to •	
identify E. coli
O and H antigen serology performed•	 ¶
Immunoassay detection of 
 Shiga toxin antigen 
Specimens tested directly or after enrichment •	
by immunoassay according to manufacturer 
recommendations 
Shiga toxin–positive specimens forwarded to public •	
health laboratory
Specimens retested by immunoassay for evidence •	
of STEC** 
Shiga toxin–positive specimens cultured for O157 •	
STEC and non-O157 STEC
Detection of Shiga toxin DNA 
 (i.e., Shiga toxin genes) 
Not typically performed•	 Specimens tested for Shiga toxin 1 gene (•	 stx1) 
and Shiga toxin 2 gene (stx2) directly or after 
enrichment††
Positive specimens cultured for O157 STEC and •	
non-O157 STEC 
 * Some testing procedures overlap between clinical and public health laboratories. When risk for STEC transmission to the public is high (e.g., workers in 
restaurants or child-care facilities), public health laboratories might conduct more of the primary STEC testing.
 † Simultaneous O157 STEC culture and Shiga toxin testing is recommended. Clinical laboratories should submit all STEC isolates and Shiga toxin–positive 
broths to a public health laboratory for additional testing.
 § Before sending the final report, public health laboratories should ensure that the isolated strain has genes for Shiga toxin, produces Shiga toxin, or has 
the H7 antigen.
 ¶ The public health laboratory may determine the O antigen or send the isolate to CDC for O antigen and H antigen determination.
 ** Public health laboratories that detect Shiga toxin by immunoassay are encouraged to use a different manufacturer kit than the one used by the clinical 
laboratory whose results they are confirming and should request the name of the kit used for each test.
 †† DNA-based Shiga toxin gene detection is not approved by the Food and Drug Administration for diagnosis of human STEC infections by clinical labora-
tories; however, public health laboratories might use this technique for confirmatory testing after internal validation.
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TABLE 4. Immunoassays approved by the Food and Drug Administration (FDA) for the diagnosis of Shiga toxin–producing 
Escherichia coli (STEC) infection
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 * Appropriate specimen for testing according to manufacturer recommendations. EIA testing of enrichment broth cultures incubated overnight (16–24 hours at 37°C [99°F]), rather 
than of stool specimens, is recommended because the amount of free fecal Shiga toxin in stools is often low (Cornick NA, Jelacic S, Ciol MA, Tarr PI. Escherichia coli O157:H7 
infections: discordance between filterable fecal Shiga toxin and disease outcome. J Infect Dis 2002;186:57–63). In addition, the manufacturer information indicates that tests 
performed on broth cultures have higher sensitivity and specificity than those performed on stool. 
 † Obtained from the manufacturer’s package insert. The standard by which each manufacturer evaluates its tests varies; a direct comparison of performance characteristics has 
not been made. Clinical laboratories should evaluate these performance characteristics and verify that they can obtain performance specifications comparable to those of the 
manufacturer before implementing a particular test system. Actual sensitivity and specificity might differ depending on the type of specimen tested.
 § Test evaluation information available from Teel LD, Daly JA, Jerris RC, et al. Rapid detection of Shiga toxin-producing Escherichia coli by optical immunoassay. J Clin Microbiol 
2007;45:3377–80.
 ¶ Test evaluation information available from Park CH Kim HJ, Hixon DL, Bubert A. Evaluation of the Duopath verotoxin test for detection of Shiga toxins in cultures of human stools. 
J Clin Microbiol 2003;41:2650–3.
 ** Enterohemorrhagic E. coli. Additional information available at http://www.mdeur.com/products/751630.htm.
 †† Test evaluation information available from Kehl K, Havens P, Behnke CE, Acheson DW. Evaluation of the premier EHEC assay for detection of Shiga toxin–producing Escherichia 
coli. J Clin Microbiol 1997;35:2051–4.
 §§ Test evaluation information available from Gavin PJ, Peterson LR, Pasquariello AC, et al. Evaluation of performance and potential clinical impact of ProSpecT Shiga toxin Escheri-
chia coli microplate assay for detection of Shiga toxin-producing E. coli in stool samples. J Clin Microbiol 2004;42:1652–6.
 ¶¶ Reversed passive latex agglutination. Test evaluation information available from Carroll KC, Adamson K, Korgenski K, et al. Comparison of a commercial reversed passive latex 
agglutination assay to an enzyme immunoassay for the detection of Shiga toxin–producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2003;22:689–92; Bettelheim KA. 
Development of a rapid method for the detection of verocytotoxin-producing Escherichia coli (VTEC). Lett Appl Microbiol 2001;33:31–5; and Beutin L, Zimmermann S, Gleier K. 
Evaluation of the VTEC-Screen “Seiken” test for detection of different types of Shiga toxin (verotoxin)-producing Escherichia coli (STEC) in human stool samples. Diagn Microbiol 
Infect Dis 2002;42:1–8.
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o157 Immunoassays
One commercial immunoassay is available to test for the 
O157 and H7 antigens in human stools and stool cultures 
(ImmunoCard STAT! E. coli O157:H7; Meridian Bioscience, 
Cincinnati, Ohio). This rapid assay may be performed either 
directly on stools or on an enrichment broth culture incubated 
overnight (16–24 hours at 37°C [99°F]). When performed 
directly on stool specimens, compared with culture for O157 
STEC, the assay has an overall sensitivity of 81% and specificity 
of 97% (85,86). This test is not recommended as a first-line or 
primary test for diagnosis, in part because 1) the assay does not 
detect non-O157 STEC serogroups, 2) not all E. coli O157 
produce Shiga toxin, and 3) no isolates will be available for 
testing at the public health laboratory. Laboratories that use 
this test should ensure that specimens in which O157 STEC 
bacteria are not detected are tested for Shiga toxin and cul-
tured for STEC; positive specimens should also be cultured 
for STEC. In clinical settings, O157 immunoassays are less 
useful than EIA tests that distinguish between Stx1 and Stx2 
for identifying patients at risk for developing severe disease.
Cell Cytotoxicity Assay
The Vero (African green monkey kidney) and HeLa cell 
lines are very sensitive to Shiga toxin because they have high 
concentrations of globotriaosylceramides Gb3 and Gb4, the 
receptors for Shiga toxin in eukaryotic cells. Sterile fecal filtrates 
prepared from fresh stool specimens or broth enrichments of 
selected colonies are inoculated onto cells and observed for typi-
cal cytopathic effect. Confirmation that the cytopathic effect 
is caused by Shiga toxin is performed by neutralization using 
anti-Stx 1 and anti-Stx 2 antibodies. Although very sensitive, 
this method is not routinely used in most clinical microbiology 
laboratories because the method requires familiarity with tis-
sue culture technique, the availability of cell monolayers, and 
specific antibodies. Testing typically takes 48–72 hours (13). 
Specialized Diagnostic Methods 
Certain specialized diagnostic methods might be used by 
public health laboratories for patients with HUS and during 
outbreak investigations. Immunomagnetic separation (IMS) 
is useful when the number of STEC organisms in a specimen 
is expected to be small (e.g., in specimens from patients who 
seek treatment ≥5 days after illness onset, in specimens from 
asymptomatic carriers, and in specimens that have been stored 
or transported improperly) (87,88). IMS beads labeled with 
O26, O103, O111, O145, or O157 antisera are commercially 
available. IMS is not approved by FDA for use on human 
specimens.
Serodiagnostic methods that measure antibody responses to 
serogroup-specific lipopolysaccharides can provide evidence of 
STEC infection (89). No such tests are commercially avail-
able in the United States. CDC uses internally validated tests 
to detect immunoglobulin M (IgM) and immunoglobulin G 
(IgG) responses to infection with serogroup O157 and IgM 
response to infection with serogroup O111 in patient sera 
obtained during outbreak investigations and for special 
purposes. 
Forwarding Specimens and 
Isolates to Public Health 
Laboratories
Specimens To Be Forwarded
All O157 STEC isolates growing on selective agar should 
be subcultured to agar slants and forwarded as soon as pos-
sible to the appropriate public health laboratory for additional 
characterization, in compliance with the recommendations of 
the receiving laboratory and shipping regulations. If agar slants 
are not available at the submitting laboratory, an acceptable 
alternative might be a swab that is heavily inoculated with 
representative growth and placed in transport medium.
Not all specimens that test positive for Shiga toxin yield an 
easily identifiable O157 STEC or non-O157 STEC colony on 
subculture. All Shiga toxin–positive specimens or broths from 
which no STEC isolate was recovered should be forwarded 
to the appropriate public health laboratory for isolation and 
additional testing; shipping of Shiga toxin–positive specimens 
or broths should not be delayed pending bacterial growth or 
isolation. Broths that cannot be shipped on the day that the 
EIA test is performed should be stored at 4°C (39°F) until they 
are prepared for shipping.
Public health laboratories should be prepared to accept 
isolates and broths for additional testing, with or without the 
primary stool specimen, that were Shiga toxin–positive in an 
EIA. Clinical laboratories should contact the appropriate public 
health laboratory to determine the laboratory’s preferences and 
applicable regulations. 
Transport Considerations
United Nations regulations (Division 6.2, Infectious 
Substances) stipulate that a verotoxigenic E. coli culture is a 
category A (United Nations number 2814) infectious sub-
stance, which is an infectious substance in a form capable of 
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causing permanent disability or life-threatening or fatal disease 
in otherwise healthy humans or animals when exposure to 
the substance occurs. The International Air Transportation 
Association (IATA) and Department of Transportation (DOT) 
have modified their shipping guidance to comply with this 
requirement (90,91). Therefore, all possible and confirmed 
O157 STEC and non-O157 STEC isolates and Shiga toxin–
positive EIA broths should be shipped as category A infectious 
substances. If the identity of the infectious material being 
transported has not been confirmed or is unknown, but the 
material might meet the criteria for inclusion in category A 
(e.g., a broth culture that is positive for Shiga toxin or a stool 
culture from a patient that might be part of an O157 STEC 
outbreak), certain IATA regulations apply (91). Both IATA and 
DOT require that all persons who package, ship, or transport 
category A infectious substances have formal, documented 
training every 2 years (92,93). 
Category A substances must be packaged in a water-tight pri-
mary receptacle. For shipment, slants or transport swabs heavily 
inoculated with representative growth are preferred to plates. 
Plates are acceptable only in rare instances in which patient 
diagnosis or management would be delayed by subculturing 
an organism to a slant for transport; shipment of plates must 
be preapproved by the receiving public health laboratory. If a 
swab is used, the shaft should be shortened to ensure a firm 
fit within the plastic sheath, and the joint should be secured 
with parafilm to prevent leakage. When shipping enrichment 
broths, the cap must fit tightly enough to prevent leakage into 
the shipping container, and parafilm should be wrapped around 
the cap to provide a better seal.
Slants, swabs of pure cultures, and plates (if approved by the 
receiving laboratory) may be shipped at ambient temperature. 
Stools in transport media, raw stools, and broths should be 
shipped with a cold pack to prevent growth of other gram-
negative flora. 
Commercial couriers vary regarding their acceptance of 
category A agents; clinical laboratories should check with 
their preferred commercial courier for current requirements. 
Shipping category A specimens by commercial couriers usu-
ally incurs a surcharge in addition to normal shipping fees. 
Category A infectious substances are not accepted by the U.S. 
Postal Service (94).
Shipping by a private (noncommercial) courier that is 
dedicated only to the transport of clinical specimens does not 
exempt specimens from DOT or IATA regulations; category 
A specimens must be packaged according to United Nations 
Division 6.2 regulations with appropriate documentation, even 
if not being transported by a commercial carrier (94). 
Based on existing specifications, laboratories should col-
laborate to develop specifications for packaging and shipping, 
which should be incorporated into a standard operating pro-
cedure and followed consistently. A United Nations–approved 
category A shipping container must be used for cultures, and 
cultures must be packaged and documented according to DOT 
and IATA regulations (95).
Interpretation of Final Results
Several tests for clinical or public health microbiology labo-
ratories are available for the detection of STEC, and they may 
be used alone or in combination. No testing method is 100% 
sensitive or specific, and the predictive value of a positive test is 
affected by the patient population that a particular laboratory 
serves. Specificity and sensitivity might be increased by using 
a combination of tests. However, when test results conflict, 
interpretation might be difficult, especially when clinical and 
public health laboratory test results are compared.
Clinical and public health laboratories document STEC 
test results in a final report (Table 2). Discordant results (e.g., 
positive immunoassay at a clinical laboratory but negative PCR 
result at a public health laboratory) might need to be discussed 
among the treating physician, public health epidemiologist, 
and clinical and public health laboratory staff members; how-
ever, the outcome of most patients’ illnesses (i.e., resolution 
of symptoms or progression to HUS) is already known by the 
time the discordant laboratory findings are resolved. Proper 
interpretation of test results, which is needed for appropriate 
patient evaluation and treatment, includes consideration of 
several factors, including whether the type of specimen tested 
was appropriate for the test (e.g., specimens from rectal swabs 
or whole stools placed in transport medium), the timing of 
the specimen collection relative to illness onset, the patient’s 
signs and symptoms, the epidemiologic context of the patient’s 
illness, whether the manufacturer instructions were followed 
precisely, and the possibility of a false-positive or false-negative 
test result. 
Clinical Considerations
Accurate, rapid identification of STEC, particularly of E. 
coli O157:H7, is critical for patient management and disease 
control. Therefore, the types of microbiologic tests chosen, 
performed, and reported and subsequent communication with 
treating clinicians are critical. Prompt and proper treatment 
of patients with a positive or presumptively positive STEC 
culture requires rapid and clear diagnostic enteric microbiology 
and reporting of data. More detailed information on clinical 
considerations and care of patients with STEC infection is 
available from recent clinical reviews (32,96,97).
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Conclusion
Accumulated findings from investigations of STEC out-
breaks, studies of sporadic STEC infections, and passive and 
active surveillance provide compelling evidence to support the 
recommendation that all stools submitted for routine testing 
to clinical laboratories from patients with community-acquired 
diarrhea should be cultured for O157 STEC and simultane-
ously tested for non-O157 STEC with an assay that detects 
Shiga toxins. These recommendations should improve the 
accuracy of diagnosing STEC infections, facilitate assessment 
of risk for severe illness, promote prompt diagnosis and treat-
ment, and improve detection of outbreaks. 
Because of the critical impact of time on diagnosis of STEC, 
treating patients, and recognizing and controlling outbreaks of 
STEC infections, attempting to isolate O157 STEC and detect 
other STEC serotypes simultaneously, rather than separately 
(i.e., conducting a Shiga toxin test to determine whether to 
culture), is recommended. Performing culture for O157 STEC 
while simultaneously testing for all STEC serotypes is critical. 
O157 STEC are responsible for most STEC outbreaks and 
most cases of severe disease; almost all strains have the virulence 
genes stx2 and eae, which are associated with severe disease. 
Detection of O157 STEC within 24 hours after specimen 
submission to the laboratory helps physicians to rapidly assess 
the patient’s risk for severe disease and to initiate measures 
to prevent serious complications, such as renal damage and 
death. Rapid isolation of the infecting organism helps public 
health officials quickly initiate measures to detect outbreaks 
and control the spread of infection. 
Because of the dynamic nature of the Shiga toxin–converting 
phages and the potential of decreased diagnostic sensitivity 
for these pathogens later during infection, future commer-
cial assays that target stable traits might improve diagnostic 
sensitivity. To facilitate diagnosis and patient management, 
future methods would also ideally allow for an assessment of 
the organism’s potential to cause severe disease (e.g., related to 
the presence of stx2, certain stx2 subtypes, and eae). Improved 
isolation methods for non-O157 STEC also are needed. As 
nucleotide sequences for more STEC strains become available, 
comparative genomic studies might identify targets that can 
be used to improve detection, virulence profiling, and isola-
tion strategies.
The Association of Public Health Laboratories, in conjunc-
tion with state and federal partners, is developing guidelines for 
receiving, testing, isolating, and characterizing STEC isolates 
and specimens in public health laboratories. That document 
will complement the guidelines in this report and will be 
available on the APHL website (http://www.aphl.org) by early 
2010. Additional information on STEC is available at http://
www.cdc.gov/ecoli. 
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